21:10 , May 9, 2019 |  BioCentury  |  Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead...
19:09 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D on Oct. 25 to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase...
13:27 , Oct 25, 2018 |  BC Extra  |  Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase III study of...
22:16 , Aug 4, 2017 |  BioCentury  |  Finance

Milestone's options

Milestone Pharmaceuticals Inc. turned positive Phase II data for etripamil into an upsized $55 million series C round, which will give the cardiovascular company leeway to expand its core program or in-license a second cardio...
19:50 , Aug 4, 2017 |  BC Week In Review  |  Clinical News

Milestone's etripamil meets in Phase II for PSVT

In May, Milestone Pharmaceuticals Inc. (Montreal, Quebec) reported data from the Phase II NODE-1 trial in 104 patients with a history of paroxysmal supraventricular tachycardia (PSVT) showing that 70, 105 and 140 mg doses of...
16:45 , Aug 4, 2017 |  BC Week In Review  |  Financial News

Milestone closes first tranche of $55M series C

On Aug. 1, Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised an undisclosed amount in the first tranche of a $55 million series C round led by new investor Novo Holdings A/S (Hellerup, Denmark). New investors Forbion...
22:01 , Aug 1, 2017 |  BC Extra  |  Financial News

Milestone raises $55M in series C

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $55 million in a series C round led by Novo Holdings A/S (Hellerup, Denmark). New investors Forbion Capital Partners and Tekla Capital Management also participated, as did existing investors...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

MSP-2017: Phase I started

Milestone began a double-blind, placebo-controlled, crossover, Australian Phase I trial to evaluate single ascending-doses of 2 intranasal formulations of MSP-2017 in healthy adult volunteers. Milestone Pharmaceuticals Inc. , Montreal, Quebec   Product: MSP-2017   Business:...
07:00 , Jun 20, 2011 |  BioCentury  |  Finance

Making the Milestone

Making the Milestone The venture arm of the Business Development Bank of Canada helped lead a C$13 million ($13.3 million) series A round last week in cardiovascular play Milestone Pharmaceuticals Inc. The financing is intended...
23:56 , Jun 13, 2011 |  BC Extra  |  Financial News

Milestone raises $13.3 million

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised C$13 million ($13.3 million) in an equity round led by new investors Pappas Ventures; the Business Development Bank of Canada; and GO Capital. Fonds de solidarite FTQ, also a...